Activities

Our research is focused on malignant brain tumours and aims to improve therapeutic options for these uncurable cancers. Patient tumors and patient derived xenograft models (PDX), which enable to translate novel treatment approaches into personalised medicine, are central to our work.

Our specific expertise and interests lie in tumour angiogenesis and invasion, tumour metabolism, and tumour cell heterogeneity and adaptability. Our research group is closely linked to the K.G. Jebsen Brain Tumour Research Center (University of Bergen, Norway), with joint research projects on glioma angiogenesis, metabolism and in vivo imaging, and has an extensive network of national and international collaborators.

Research projects

  • ADAPT: Adaptive capacities of glioblastoma: is there a role for cancer stem cells?
  • METABO: Aberrant tumour metabolism in gliomas.
  • INVGBM: Targeting glioma cell invasion.
  • CREG: Chemoresistance related RNAs in glioblastoma.
  • ANIMIX: Establishment of a national in vivo imaging platform.
  • GLIOTRAIN: Exploiting GLIOblastoma intractability to address European research TRAINing needs in translational brain tumour research, cancer systems medicine and integrative multi-omics (GLIOTRAIN Newsletters)

     

Featured Publications

Longitudinal molecular trajectories of diffuse glioma in adults.

  • Neuro-Oncology Laboratory
November 20, 2019
2019 Nov. Nature.10.1038/s41586-019-1775-1. [Online ahead of print].
By:
  • Barthel FP
  • Johnson KC
  • Varn FS
  • Moskalik AD
  • Tanner G
  • Kocakavuk E
  • Anderson KJ
  • Abiola O
  • Aldape K
  • Alfaro KD
  • Alpar D
  • Amin SB
  • Ashley DM
  • Bandopadhayay P
  • Barnholtz-Sloan JS
  • Beroukhim R
  • Bock C
  • Brastianos PK
  • Brat DJ
  • Brodbelt AR
  • Bruns AF
  • Bulsara KR
  • Chakrabarty A
  • Chakravarti A
  • Chuang JH
  • Claus EB
  • Cochran EJ
  • Connelly J
  • Costello JF
  • Finocchiaro G
  • Fletcher MN
  • French PJ
  • Gan HK
  • Gilbert MR
  • Gould PV
  • Grimmer MR
  • Iavarone A
  • Ismail A
  • Jenkinson MD
  • Khasraw M
  • Kim H
  • Kouwenhoven MCM
  • LaViolette PS
  • Li M
  • Lichter P
  • Ligon KL
  • Lowman AK
  • Malta TM
  • Mazor T
  • McDonald KL
  • Molinaro AM
  • Nam DH
  • Nayyar N
  • Ng HK
  • Ngan CY
  • Niclou SP
  • Niers JM
  • Noushmehr H
  • Noorbakhsh J
  • Ormond DR
  • Park CK
  • Poisson LM
  • Rabadan R
  • Radlwimmer B
  • Rao G
  • Reifenberger G
  • Sa JK
  • Schuster M
  • Shaw BL
  • Short SC
  • Smitt PAS
  • Sloan AE
  • Smits M
  • Suzuki H
  • Tabatabai G
  • Van Meir EG
  • Watts C
  • Weller M
  • Wesseling P
  • Westerman BA
  • Widhalm G
  • Woehrer A
  • Yung WKA
  • Zadeh G
  • Huse JT
  • De Groot JF
  • Stead LF
  • Verhaak RGW
  • Consortium G.

The soluble form of pan-RTK inhibitor and tumor suppressor LRIG1 mediates downregulation of AXL through direct protein-protein interaction in Glioblastoma.

  • Neuro-Oncology Laboratory
  • Multiomics Data Science
  • Immuno-Pharmacology and Interactomics
September 06, 2019
2019 Sep. Neuro-Oncology Advances. Accepted.
By:
  • Neirinckx V
  • Hau A-C
  • Schuster A
  • Fritah S
  • Tiemann K
  • Klein E
  • Nazarov PV
  • Matagne A
  • Szpakowska M
  • Meyrath M
  • Chevigné A
  • Schmidt MHH
  • Niclou SP.
See all publications

Contacts

Simone Niclou

Ph.D.

84, rue Val Fleuri
L-1526 Luxembourg
Luxembourg
Tel. : +352 26970-273

Odoo image and text block



anna golebiewska

Ph.D.

84, rue Val Fleuri
L-1526 Luxembourg
LUXEMBOURG
Tel. : +352 26970-244